Search

C14H20Cl2N4O4Zn, monoclinic, P21/n (no. 14), a = 8.562(2) Å, b = 27.953(8) Å, c = 8.804(2) Å, β = 117.092(4)°, V = 1875.9(9) Å3, Z = 4, R gt(F) = 0.0441, wR ref(F 2) = 0.1031, T = 296 K.

C6H6N2O2, monoclinic P21/c (no. 14), a = 6.7909(2) Å, b = 23.9261(7) Å, c = 7.5103(2) Å, β = 95.265(2)°, V = 1215.12(6) Å3, Z = 8, R gt(F) = 0.0574, wR ref(F 2) = 0.1439, T = 293.

Current understanding holds that Klinefelter syndrome (KS) is not inherited, but arises randomly during meiosis. Whether there is any genetic basis for the origin of KS is unknown. Here, guided by our identification of some USP26 variations apparently associated with KS, we found that knockout of Usp26 in male mice resulted in the production of 41, XXY offspring. USP26 protein is localized at the XY body, and the disruption of Usp26 causes incomplete sex chromosome pairing by destabilizing TEX11. The unpaired sex chromosomes then result in XY aneuploid spermatozoa. Consistent with our mouse results, a clinical study shows that some USP26 variations increase the proportion of XY aneuploid spermatozoa in fertile men, and we identified two families with KS offspring wherein the father of the KS patient harbored a USP26-mutated haplotype, further supporting that paternal USP26 mutation can cause KS offspring production. Thus, some KS should originate from XY spermatozoa, and paternal USP26 mutations increase the risk of producing KS offspring.

Introduction: Diabetic peripheral neuropathy (DPN), a widely prevalent complication in patients with type 2 diabetes, exerts a significant influence on patients' overall health and financial circumstances. Photobiomodulation therapy is one of the means of physical therapy for DPN. Although preliminary findings suggest the efficacy of photobiomodulation therapy in alleviating peripheral neuropathy, the existing literature lacks substantial evidence regarding its safety and effectiveness specifically in the context of diabetes-related peripheral neuropathy. Therefore, we plan to arrive at more distinct findings through systematic evaluation and meta-analysis. Methods: We will conduct a comprehensive search for studies published from the beginning until October 1, 2023, using various databases including Web of Science, Embase, Cochrane Library, PubMed, AMED, Wanfang database, VIP database, China National Knowledge Infrastructure, and the Chinese Biomedical Literature database. Simultaneously, we will also search for the WHO International Clinical Trial Registration Platform, China Clinical Trial Registration Platform, and Clinical Trials.gov. Gray literature will be retrieved using Google Scholar and opengrey.edu. Only randomized controlled trials in Chinese and English were included, with no restrictions on publication status. The primary outcomes will include change of symptom scores, change of nerve conduction velocity. Additional outcomes will encompass quality of life, change in pain, blood glucose levels after fasting and 2 hours after eating, levels of glycosylated hemoglobin, and any adverse events associated with photobiomodulation therapy. Reman V.5.4 and R language will be used for the meta-analysis. Assessment of potential bias will be conducted through Cochrane risk of bias 2 tool (RoB 2.0) and Physiotherapy Evidence Database (PEDro) scale. Registration: PROSPERO (registration number: CRD42023466586). Discussion: This meta-analysis aims to assess the efficacy and safety of photobiomodulation therapy as a potential treatment for diabetic peripheral neuropathy (DPN), and providing a straightforward and convenient therapeutic for patients. Additionally, it expands the range of treatment alternatives available to healthcare professionals managing DPN. [ABSTRACT FROM AUTHOR]

C6H6N2O2, monoclinic P21/c (no. 14), a = 6.7909(2) Å, b = 23.9261(7) Å, c = 7.5103(2) Å, β = 95.265(2)°, V = 1215.12(6) Å3, Z = 8, Rgt(F) = 0.0574, wRref(F2) = 0.1439, T = 293. [ABSTRACT FROM AUTHOR]

C14H20Cl2N4O4Zn, monoclinic, P21/n (no. 14), a = 8.562(2) Å, b = 27.953(8) Å, c = 8.804(2) Å, β = 117.092(4)°, V = 1875.9(9) Å3, Z = 4, Rgt(F) = 0.0441, wRref(F2) = 0.1031, T = 296 K. [ABSTRACT FROM AUTHOR]

C6H6N2O2, monoclinic P21/c (no. 14), a = 6.7909(2) Å, b = 23.9261(7) Å, c = 7.5103(2) Å, β = 95.265(2)°, V = 1215.12(6) Å3, Z = 8, Rgt(F) = 0.0574, wRref(F2) = 0.1439, T = 293. [ABSTRACT FROM AUTHOR]

Coronavirus disease 2019 (COVID‐19) has become a global epidemic, and there is no specific treatment for anti‐COVID‐19 drugs. However, treatment of COVID‐19 using Chinese herbal medicine (CHM) has been widely practiced in China. PubMed, Embase, Cochrane Library, CNKI, Wanfang and VIP databases were searched to evaluate the efficacy and safety of CHM in the treatment of COVID‐19. Twenty‐six studies were included in this meta‐analysis. The included cases were all patients diagnosed with COVID‐19 according to the "New Coronary Virus Pneumonia Diagnosis and Treatment Program," with a total of 2,407 cases. Patients were treated with CHM, including 36 prescriptions, and 105 flavors of CHM were included. The results of the meta‐analysis showed that the CHM group improved in lung CT, clinical cure rate, clinical symptom score and time to negative for viral nucleic acid. However, this study still has many limitations due to the limited number of included studies. Therefore, high‐quality RCT studies are needed to provide more reliable evidence for CHM treatment of COVID‐19. In conclusion, CHM may significantly improve the clinical manifestations and laboratory indicators of patients with COVID‐19. In addition, no serious adverse reactions were found after CHM treatment. Therefore, CHM may be used as a potential candidate for COVID‐19. Highlights: COVID‐19 has become a global epidemic, and there is no specific treatment for anti‐COVID‐19 drugs.CHM has made a new breakthrough in the treatment of COVID‐19.CHM may relieve lung CT images of COVID‐19 patients.CHM may improve clinical symptoms of COVID‐19 patients.CHM may inhibit the expression of inflammatory factors in patients with COVID‐19. [ABSTRACT FROM AUTHOR]